A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients With Relapsed or Refractory Solid Organ Tumors

Trial Profile

A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients With Relapsed or Refractory Solid Organ Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Oct 2017

At a glance

  • Drugs Navitoclax (Primary) ; Sorafenib
  • Indications Liver cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Jul 2017 Status changed from suspended to recruiting.
    • 19 May 2017 Status changed from recruiting to suspended to allow for patient assessment as per protocol.
    • 24 Apr 2017 Planned number of patients changed from 10 to 44.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top